# Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.

*biotech · news · 2026-05-12 · PR Newswire UK*

## Key points

- Isomorphic Labs has raised $2.1 billion in Series B funding led by Thrive Capital.
- Their AI drug design engine IsoDDE now bridges structure prediction and real-world drug discovery.
- IsoDDE demonstrates predictive fidelity for novel biological systems across multiple therapeutic areas.
- Strategic partnerships include Novartis, Lilly, and Johnson & Johnson validating Isomorphic's AI-first approach.
- Capital infusion will help globally scale their pipeline and hire multidisciplinary AI and clinical talent.

**Companies:** Alphabet, GV, Thrive Capital, Temasek, Isomorphic Labs, MGX
**Countries:** United Kingdom, United States, Switzerland

[Read the full story on PR Newswire UK](https://www.prnewswire.co.uk/news-releases/isomorphic-labs-secures-2-1-billion-funding-to-scale-its-ai-drug-design-engine-302769702.html)

---

Canonical: https://newsio.io/n/5c7cfc40-e7dc-4b1c-b96f-3bbec3dbac7e/isomorphic-labs-will-use-the-funding-to-power-its-world-leading-ai-drug-design-e
Summarized by Newsio from PR Newswire UK. https://newsio.io/how-it-works